PolyPid’s (PYPD) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of PolyPid (NASDAQ:PYPD) in a report released on Thursday,Benzinga reports. They currently have a $13.00 price target on the stock. HC Wainwright also issued estimates for PolyPid’s FY2029 earnings at $0.87 EPS and FY2030 earnings at $1.65 EPS.

A number of other analysts have also recently commented on the stock. Craig Hallum set a $12.00 target price on shares of PolyPid in a report on Wednesday, July 22nd. Oppenheimer assumed coverage on shares of PolyPid in a research report on Tuesday, October 27th. They set an “outperform” rating and a $10.00 price objective for the company. Wall Street Zen upgraded PolyPid from a “hold” rating to a “buy” rating in a research note on Saturday, October 31st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of PolyPid in a report on Friday, September 18th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $11.67.

PolyPid Trading Down 2.2%

PYPD stock traded down $0.14 during trading on Thursday, reaching $6.26. The stock had a trading volume of 193,133 shares, compared to its average volume of 168,040. PolyPid has a 52 week low of $3.50 and a 52 week high of $7.15. The stock’s 50 day moving average is $5.37 and its two-hundred day moving average is $4.80. The firm has a market cap of $119.44 million, a PE ratio of -4.64 and a beta of 1.43.

PolyPid (NASDAQ:PYPD) last released its quarterly earnings results on Wednesday, November 11th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.91 by ($1.15). The business had revenue of $30.00 million during the quarter, compared to analyst estimates of $30.00 million. On average, research analysts anticipate that PolyPid will post -0.44 EPS for the current year.

Institutional Trading of PolyPid

A number of hedge funds and other institutional investors have recently modified their holdings of PYPD. AIGH Capital Management LLC bought a new stake in shares of PolyPid during the 2nd quarter valued at $7,644,000. Marshall Wace LLP boosted its holdings in PolyPid by 73.7% in the 3rd quarter. Marshall Wace LLP now owns 199,745 shares of the company’s stock worth $1,053,000 after buying an additional 84,731 shares during the period. ADAR1 Capital Management LLC bought a new position in PolyPid in the 2nd quarter worth $528,000. Symmetry Peak Management LLC bought a new position in PolyPid in the 2nd quarter worth $512,000. Finally, J. Goldman & Co LP purchased a new stake in PolyPid in the 2nd quarter worth $504,000. 26.47% of the stock is owned by hedge funds and other institutional investors.

About PolyPid

PolyPid Ltd. is an Israeli clinical-stage biopharmaceutical company developing products designed to deliver medicines locally and over an extended period. Its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology is intended to control the release of drugs at the site where they are administered. The company’s lead product candidate, D-PLEX100, uses the antibiotic doxycycline and is designed to be applied during surgery to provide sustained local drug delivery for the prevention of surgical-site infections.